Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | June 26, 2017 |
End Date: | June 2022 |
Contact: | Medical Affairs Agios Pharmaceuticals, Inc. |
Email: | medinfo@agios.com |
Phone: | 1.833.228.8474 |
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized,
placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib)
+ azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML
who are considered appropriate candidates for non-intensive therapy. The primary endpoint is
Overall Survival (OS). The key secondary efficacy endpoints are Event free Survival (EFS),
rate of complete remission (CR), Rate of CR and complete remission with partial hematologic
recovery (CRh), and overall response rate (ORR). Subjects eligible for study treatment based
on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched placebo,
both administered in combination with subcutaneous (SC) or intravenous (IV) azacitidine. An
estimated 392 subjects will participate in the study.
placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib)
+ azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML
who are considered appropriate candidates for non-intensive therapy. The primary endpoint is
Overall Survival (OS). The key secondary efficacy endpoints are Event free Survival (EFS),
rate of complete remission (CR), Rate of CR and complete remission with partial hematologic
recovery (CRh), and overall response rate (ORR). Subjects eligible for study treatment based
on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched placebo,
both administered in combination with subcutaneous (SC) or intravenous (IV) azacitidine. An
estimated 392 subjects will participate in the study.
Inclusion Criteria:
1. Be ≥ 18 years of age.
2. Have previously untreated AML, defined according to WHO criteria, with ≥ 20% leukemic
blasts in the bone marrow. Subjects with extramedullary disease alone (ie, no
detectable bone marrow and no detectable peripheral blood AML) are not eligible for
the study.
3. Have an isocitrate dehydrogenase 1 (IDH1) mutation
4. Have an ECOG Performance Status score of 0 to 2.
5. Have adequate hepatic function
6. Have adequate renal function
7. Have agreed to undergo serial blood and bone marrow sampling.
8. Be able to understand and willing to sign an informed consent form (ICF).
9. Be willing to complete Quality of Life assessments during the study
10. If female with reproductive potential, must have a negative serum pregnancy test prior
to the start of study therapy. Females of reproductive potential, as well as fertile
men and their female partners of reproductive potential, must agree to use 2 effective
forms of contraception.
Exclusion Criteria:
1. Are candidates for and willing to receive intensive IC for their AML.
2. Have received any prior treatment for AML with the exception of hydroxyurea.
3. Have received a hypomethylating agent for myelodysplastic syndrome (MDS).
4. Subjects who had previously received an experimental agent for MDS may not be
randomized until a washout period has elapsed since the last dose of that agent.
5. Have received prior treatment with an IDH1 inhibitor.
6. Have a known hypersensitivity to any of the components of AG-120, matched placebo, or
azacitidine.
7. Are female and pregnant or breastfeeding.
8. Have an active, uncontrolled, systemic fungal, bacterial, or viral infection without
improvement despite appropriate antibiotics, antiviral therapy, and/or other
treatment.
9. Have a prior history of cancer other than MDS or myeloproliferative disorder, unless
the subject has been free of the disease for ≥ 1 year prior to the start of study
treatment.
10. Have had significant active cardiac disease within 6 months prior to the start of
study treatment
11. Have any condition that increases the risk of abnormal ECG or cardiac arrhythmia
12. Have a condition that limits the ingestion or absorption of drugs administered by
mouth
13. Have uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic
BP > 100 mmHg).
14. Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or
known CNS leukemia.
15. Have immediate, life-threatening, severe complications of leukemia, such as
uncontrolled bleeding, pneumonia with hypoxia or sepsis, and/or disseminated
intravascular coagulation.
16. Have any other medical or psychological condition deemed by the Investigator to be
likely to interfere with the subject's ability to give informed consent or participate
in the study.
We found this trial at
24
sites
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
New York Medical College The College was founded in 1860 by a group of New...
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
Click here to add this to my saved trials
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Gabrail Cancer Center Since 1990, Gabrail Cancer Center has built a national reputation for excellence...
Click here to add this to my saved trials
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
Click here to add this to my saved trials
Baylor Research Institute Baylor Research Institute (BRI) is a dedicated research center for finding prevention...
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
Click here to add this to my saved trials
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
Click here to add this to my saved trials